Equities

Proteome Sciences PLC

PRM:LSE

Proteome Sciences PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.51
  • Today's Change0.0000000000000004 / 0.00%
  • Shares traded202.00k
  • 1 Year change-19.31%
  • Beta0.1286
Data delayed at least 20 minutes, as of May 03 2024 16:25 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Proteome Sciences PLC's revenues fell -35.37% from 7.78m to 5.03m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 1.33m to a loss of 2.44m.
Gross margin32.76%
Net profit margin-48.59%
Operating margin-32.24%
Return on assets-20.45%
Return on equity--
Return on investment--
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Proteome Sciences PLC fell by 1.97m. Cash Flow from Investing was negative at 424.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 481.00k for operations while cash used for financing totalled 1.06m.
Cash flow per share-0.0066
Price/Cash flow per share--
Book value per share-0.0104
Tangible book value per share-0.0247
More ▼

Balance sheet in GBPView more

Proteome Sciences PLC appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.3338
Quick ratio0.2667
Total debt/total equity--
Total debt/total capital1.29
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -293.01%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-294.82
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.